Chelsea Counsel Company’s Ionis Pharmaceuticals IONS Stock Holding History

Chelsea Counsel Company’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-4,200	Closed	-$242K	–	161
2015 Q2	$242K	Buy	+4,200	New	+$267K	0.05%	139

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Chelsea Counsel Company's IONS Position: Q3 2015 in Review

Chelsea Counsel Company sold out of Ionis Pharmaceuticals (IONS) in Q3 2015, closing a stake of 4,200 shares — an estimated $242K sold.

Chelsea Counsel Company first reported a position in IONS in Q2 2015 and held it in 1 quarter. The position peaked at $242K in Q2 2015. 314 funds tracked by Wall St. Rank hold IONS as of Q3 2015.

Chelsea Counsel Company reported no remaining Ionis Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
Chelsea Counsel Company sold 4,200 Ionis Pharmaceuticals shares in Q3 2015, an estimated $242K.
Chelsea Counsel Company first reported a position in Ionis Pharmaceuticals in Q2 2015 and held it in 1 quarter.
Chelsea Counsel Company's Ionis Pharmaceuticals position peaked at $242K in Q2 2015.
314 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2015.

Based on Chelsea Counsel Company's 13F filing for Q3 2015, filed 22 Dec 2015.